




Supplementary figures and figure legends




Supple 1. Negative control of CD68 immunostaining (no primary antibody of CD68). Presentation of DAPI stained nuclei (**a, c, e,**) and CD68 negative immunostaining (**b, d, f**) in the peri-infarct region of **the** striatum of Vehicle, PBS, and CLP treated group. Scar bar=50 μ m.



Supple 2. Negative control of MBP immunostaining (no primary antibody of MBP). Presentation of MBP negative immunostaining in the peri-infarct region of **the** striatum of Vehicle, PBS, and CLP treated group. Scar bar=50 μ m.



Supple 3. Negative control of Iba1 immunostaining (no primary antibody of Iba1). Presentation of DAPI stained nuclei (**a1-f1**) and Iba1 negative immunostaining (**b2-f2**) in the peri-infarct region of **the** cortex and striatum of Vehicle, PBS, and CLP treated group. Scar bar=50 μ m.



Supple 4. Negative control of CD31 immunostaining (no primary antibody of CD31). Presentation of DAPI stained nuclei (**a, c, e,**) and CD31 negative immunostaining (**b, d, f**) in the peri-infarct region of **the** striatum of Vehicle, PBS, and CLP treated group. Scar bar=50 μ m.